晶泰科技 机械臂控制岗 深圳-30k-60k ·13薪 任职要求： 硕士及以上学历，计算机科学、自动化、电子工程、控制工程等相关专业；3年以 上 机 器 人 控 制 算 法 开 发 经 验 ； 熟 悉 常 用 的 控 制 算 法 ( 如 PID 、 LQR 、 MPC 等 ) 及 其 应 用 ； 精 通 C/C++ 、 Py thon 等 编 程 语 言 ， 具 备 良 好 的 编 程 能 力 和 代 码 管 理 能 力 ； 熟 悉 优 化 算 法 (QP 、 SQP)、轨迹规划(TOPP)或接触动力学建模；熟悉传感器数据处理及融合技术，能够进行仿真 和 实 际 测 试 ； 具 备 良 好 的 问 题 解 决 能 力 和 团 队 合 作 精 神 ； 具 有 较 强 的 学 习 能 力 和 技 术 创 新 意 识。 点击免费限量礼盒 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 仪粉er们，今天是精品仪器销售、售前类职位专辑 哦！ 仪器精英，热招职位 Ho t r e c r u itme n t p o siti o n s 安 ...

Group 1 - The core viewpoint of the article highlights that Laibotai Technology has been re-certified as a national-level "specialized and innovative" small giant enterprise, effective for another three years [1] - Laibotai Technology's revenue composition for the year 2024 is detailed, with other sectors accounting for 38.69%, environmental protection at 18.46%, medical testing at 6.91%, disease control at 6.79%, research institutions/universities at 6.61%, food and drug industry at 6.51%, geology/minerals/energy at 5.84%, and third-party testing at 5.6% [1] - The current market capitalization of Laibotai Technology is reported to be 2.4 billion yuan [2]

证券日报网讯 11月25日晚间，莱伯泰科发布公告称，北京莱伯泰科仪器股份有限公司（以下简称"公 司"）已于2022年被认定为第四批国家级专精特新"小巨人"企业称号，有效期三年。根据北京市经济和 信息化局近日发布的《关于北京市第七批专精特新"小巨人"企业和2025年专精特新"小巨人"复核通过企 业名单进行公示的通知》，公司已通过复核并继续被授予国家级专精特新"小巨人"企业称号，有效期三 年。 （文章来源：证券日报） ...

北京莱伯泰科仪器股份有限公司 关于公司国家级专精特新"小巨人" 复核通过的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 基本情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2022 年被认定为 第四批国家级专精特新"小巨人"企业称号，有效期三年。 证券代码：688056 证券简称：莱伯泰科 公告编号：2025-038 1 三、 风险提示 公司本次通过国家级专精特新"小巨人"复核，不会对公司当期经营业绩产生 重大影响，敬请广大投资者谨慎投资，注意投资风险。 四、 备查文件 《北京市经济和信息化局关于北京市第七批专精特新"小巨人"企业和 2025 年专精特新"小巨人"复核通过企业名单进行公示的通知》 特此公告。 北京莱伯泰科仪器股份有限公司董事会 根据北京市经济和信息化局近日发布的《关于北京市第七批专精特新"小巨 人"企业和 2025 年专精特新"小巨人"复核通过企业名单进行公示的通知》，公司 已通过复核并继续被授予国家级专精特新"小巨人"企业称号，有效期三年。 二、 对公司的影响 国家级专 ...

Core Viewpoint - The company, 莱伯泰科, has successfully passed the national re-evaluation and continues to hold the title of "National Specialized and Innovative 'Little Giant' Enterprise" for another three years, reflecting government recognition of its innovation capabilities and market competitiveness [1] Group 1 - The company was recognized as a "Little Giant" enterprise in 2022, with the title valid for three years [1] - The recent announcement from the Beijing Economic and Information Technology Bureau confirms the company's re-evaluation and continued recognition [1] - This recognition enhances the company's visibility and market competitiveness, positively impacting its future development [1] Group 2 - The company aims to leverage this recognition to focus on its core business and innovation-driven development [1] - There is an emphasis on team building and market expansion to enhance core competitiveness and industry influence [1] - The goal is to become a leading and globally influential manufacturer in the instrumentation and meter industry [1]

莱伯泰科(688056.SH)发布公告，公司已于2022年被认定为第四批国家级专精特新"小巨人"企业称号， 有效期三年。根据北京市经济和信息化局近日发布的《关于北京市第七批专精特新"小巨人"企业和2025 年专精特新"小巨人"复核通过企业名单进行公示的通知》，公司已通过复核并继续被授予国家级专精特 新"小巨人"企业称号，有效期三年。 公司本次成功通过国家级专精特新"小巨人"复核，体现了相关政府部门对公司在持续创新能力、专业化 发展战略、市场竞争优势、品牌影响力等多维度的认可，有利于提高公司的知名度及市场竞争力，对公 司未来发展将产生积极的影响。公司将以此为契机，持续聚焦主业，秉持以创新研发作为发展的核心驱 动力，继续注重团队建设及市场开拓，不断提升公司核心竞争力和行业影响力，努力成为行业领先、具 有全球影响力的仪器仪表制造企业。 ...

Investment Rating - The report adjusts the investment rating to "Recommended" for the company, indicating an expected outperformance of 10%-20% relative to the benchmark index over the next six months [9][20]. Core Insights - The company reported a 23% year-on-year growth in non-recurring net profit for Q3, indicating a potential for new product launches to drive future growth [2][9]. - Despite a decline in revenue for the first three quarters of 2025, the company achieved a slight increase in net profit for Q3, suggesting an improving trend in profitability [2][9]. - The company’s core product received authoritative recognition, and new products are being launched, which are expected to contribute to future growth [9]. - The company has successfully expanded its overseas business, with foreign revenue increasing by 14.76% year-on-year, now accounting for 20.24% of total revenue [9]. Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 285 million yuan, a decrease of 8.43% year-on-year, and a net profit of 33 million yuan, down 7.26% year-on-year [2]. - The Q3 revenue was 93 million yuan, down 4.22% year-on-year, while the net profit for Q3 was 11 million yuan, up 1.76% year-on-year [2]. - The company’s gross margin for the first three quarters of 2025 was 45.80%, an increase of 0.94 percentage points year-on-year [9]. Future Projections - The company is expected to see net profits of 43 million yuan, 54 million yuan, and 66 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 10.8%, 24.8%, and 21.6% [9]. - The target price for the company is set at 40.1 yuan, reflecting a 13% upside from the current price of 35.48 yuan [4][9].

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Market Overview - The Shanghai Composite Index closed at 4017.94 points, above the five-day moving average, with an increase of 0.44% [1] - The total trading volume of A-shares reached 12,733.37 million yuan [1] Stocks Performance - A total of 1,085 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Tianhong Lithium Battery (17.41%) - Baiwei Storage (11.81%) - Derui Lithium Battery (8.69%) [1] Detailed Stock Data - The following table summarizes the performance of selected stocks that broke the five-day moving average: | Stock Code | Stock Name | Daily Change (%) | Turnover Rate (%) | Five-Day MA (yuan) | Latest Price (yuan) | Deviation Rate (%) | |------------|----------------|------------------|--------------------|---------------------|---------------------|---------------------| | 920252 | Tianhong Lithium| 26.37 | 28.72 | 31.75 | 37.28 | 17.41 | | 688525 | Baiwei Storage | 15.92 | 10.86 | 130.71 | 146.14 | 11.81 | | 920523 | Derui Lithium | 14.66 | 12.36 | 30.80 | 33.48 | 8.69 | | 301162 | Guoneng Rixin | 10.76 | 4.41 | 58.82 | 63.60 | 8.13 | | 300584 | Haichen Pharma | 12.07 | 15.81 | 56.42 | 60.80 | 7.77 | | 300432 | Fulian Precision | 13.30 | 7.30 | 19.13 | 20.61 | 7.73 | | 603966 | Falan Technology | 10.03 | 10.44 | 11.22 | 12.07 | 7.56 | | 002208 | Hefei Urban Construction | 10.01 | 14.27 | 11.98 | 12.86 | 7.33 | | 000633 | Alloy Investment | 10.00 | 3.43 | 6.97 | 7.48 | 7.32 | | 301358 | Hunan Yunan | 11.64 | 5.91 | 82.36 | 88.27 | 7.18 | | 002227 | Aotexun | 9.99 | 6.24 | 13.88 | 14.87 | 7.12 | | 001266 | Hongying Intelligent | 10.01 | 10.99 | 30.78 | 32.97 | 7.12 | | 003022 | Lianhong New Technology | 10.00 | 1.46 | 20.88 | 22.32 | 6.91 | | 301379 | Tianshan Electronics | 9.65 | 11.89 | 28.21 | 30.10 | 6.70 | | 603188 | Yabang Shares | 10.02 | 8.83 | 5.25 | 5.60 | 6.67 | | 600686 | Jinlong Automobile | 9.08 | 6.54 | 15.43 | 16.46 | 6.66 | | 002108 | Cangzhou Ming | 10.04 | 8.50 | 4.93 | 5.26 | 6.61 [1][2]

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-037 重要内容提示： 投资者可于 2025 年 11 月 12 日 （星期三） 至 11 月 18 日 （星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqtzb@labtechgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 19 日（星 期三）16:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行 交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2025 年 11 月 19 日（星期三）16:00-17: ...